Ikarian Capital, LLC Nuvation Bio Inc. Transaction History

Ikarian Capital, LLC

$714 Million
Q1 2025

A detailed history of Ikarian Capital, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 619,258 shares of NUVB stock, worth $1.26 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

619,258

Previous 83,407 642.45%

Holding current value

$1.26 Million

Previous $221,000 392.76%

% of portfolio

0.15%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.76 - $3.25 $943,097 - $1.74 Million	535,851 Added 642.45%	619,258 $1.09 Million
Q4 2024 Feb 14, 2025	BUY	$2.01 - $3.01 $251 - $376	125 Added 0.15%	83,407 $221,000
Q3 2024 Nov 14, 2024	SELL	$2.3 - $3.83 $632,500 - $1.05 Million	-275,000 Reduced 76.76%	83,282 $191,000
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $709,500 - $1.01 Million	-275,000 Reduced 43.42%	358,282 $1.05 Million
Q1 2024 May 15, 2024	SELL	$1.46 - $3.97 $860,772 - $2.34 Million	-589,570 Reduced 48.21%	633,282 $2.31 Million
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.1 $1.54 Million - $2.57 Million	1,222,852 New	1,222,852 $1.64 Million
Q2 2022 Aug 12, 2022	SELL	$3.24 - $5.85 $691,124 - $1.25 Million	-213,310 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.6 - $8.83 $61,225 - $117,527	13,310 Added 6.65%	213,310 $1.12 Million
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $1.55 Million - $2.01 Million	200,000 New	200,000 $1.7 Million
Q2 2021 Aug 16, 2021	SELL	$9.22 - $14.48 $2.31 Million - $3.62 Million	-250,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.0 - $14.57 $2.25 Million - $3.64 Million	250,000 New	250,000 $2.61 Million

Others Institutions Holding NUVB

# of Institutions

167

Shares Held

156M

Call Options Held

4.6K

Put Options Held

154K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $441M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Nuvation Bio Inc. Transaction History